Comment & Analysis

If lowering tax rates was not the objective of this year’s wave of corporate inversions, as many ...

With Salix Pharmaceuticals trading up as high as 11% before the markets opened this morning on ...

DBV Technologies is wasting no time capitalising on positive results from a phase IIb trial of its ...




Therapeutic Focus

Market Moving Events

EP Vantage Interviews